Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.

Yoshiyuki MiyazawaTakanori ShimizuYoshitaka SekineSeiji AraiAkira OhtsuYuji FujizukaMasashi NomuraHidekazu KoikeHiroshi MatsuiKazuhiro Suzuki

Published in: IJU case reports (2022)

Cisplatin and olaparib may overlap in response due to their medicinal action. It may be useful to consider genetic testing in some CRPC patients who have responded to cisplatin.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis